Quarterly ResultMay 8, 2026, 05:07 PM
Matinas BioPharma Q1 Net Loss $(1.92)M; Going Concern Warning
AI Summary
Matinas BioPharma reported a net loss of $(1.92) million for Q1 2026, an increase from $(1.66) million in Q1 2025. The company's cash and cash equivalents significantly decreased by 40% to $2.40 million as of March 31, 2026, leading to a "substantial doubt" about its ability to continue as a going concern. The company is focused on monetizing MAT2203, conserving cash, and exploring strategic options like partnerships or a merger.
Key Highlights
- Substantial doubt exists about Matinas BioPharma's ability to continue as a going concern.
- Net loss for Q1 2026 increased to $(1.92) million from $(1.66) million in Q1 2025.
- Cash and cash equivalents decreased 40% to $2.40 million as of March 31, 2026.
- Total assets decreased 18.5% to $5.87 million, while total liabilities increased 19.9% to $2.85 million.
- Research and development expenses were $0 in Q1 2026, down 100% from $85 thousand in Q1 2025.
- General and administrative expenses increased 4.0% to $1.94 million in Q1 2026.
- Net cash used in operating activities improved 20.2% to $(1.60) million in Q1 2026.
- Bridgewater lease terminated post-period for a $765 thousand payment.